Profiles Header - Harvard Catalyst Profiles Header – Harvard Catalyst

Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

David P. Ryan, M.D.

Title
Institution
Department
Address
Phone
Fax

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Wong RL, El-Jawahri A, D'Arpino SM, Fuh CX, Johnson PC, Lage DE, Irwin KE, Pirl WF, Traeger L, Cashavelly BJ, Jackson VA, Greer JA, Ryan DP, Hochberg EP, Temel JS, Nipp RD. Use of Antidepressant Medications Moderates the Relationship Between Depressive Symptoms and Hospital Length of Stay in Patients with Advanced Cancer. Oncologist. 2018 Aug 06. PMID: 30082486.
    View in: PubMed
  2. Yozu M, Johncilla ME, Srivastava A, Ryan DP, Cusack JC, Doyle L, Setia N, Yang M, Lauwers GY, Odze RD, Misdraji J. Histologic and Outcome Study Supports Reclassifying Appendiceal Goblet Cell Carcinoids as Goblet Cell Adenocarcinomas, and Grading and Staging Similarly to Colonic Adenocarcinomas. Am J Surg Pathol. 2018 Jul; 42(7):898-910. PMID: 29579011.
    View in: PubMed
  3. Murphy JE, Wo JY, Ryan DP, Jiang W, Yeap BY, Drapek LC, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Faris JE, Zhu AX, Goyal L, Lillemoe KD, DeLaney TF, Fernández-Del Castillo C, Ferrone CR, Hong TS. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol. 2018 Jul 01; 4(7):963-969. PMID: 29800971.
    View in: PubMed
  4. Wo JY, Niemierko A, Ryan DP, Blaszkowsky LS, Clark JW, Kwak EL, Lillemoe KD, Drapek LN, Zhu AX, Allen JN, Faris JE, Murphy JE, Nipp R, Fernandez-Del Castillo C, Ferrone CR, Hong TS. Tolerability and Long-term Outcomes of Dose-Painted Neoadjuvant Chemoradiation to Regions of Vessel Involvement in Borderline or Locally Advanced Pancreatic Cancer. Am J Clin Oncol. 2018 Jul; 41(7):656-661. PMID: 28134673.
    View in: PubMed
  5. Patra KC, Kato Y, Mizukami Y, Widholz S, Boukhali M, Revenco I, Grossman EA, Ji F, Sadreyev RI, Liss AS, Screaton RA, Sakamoto K, Ryan DP, Mino-Kenudson M, Castillo CF, Nomura DK, Haas W, Bardeesy N. Mutant GNAS drives pancreatic tumourigenesis by inducing PKA-mediated SIK suppression and reprogramming lipid metabolism. Nat Cell Biol. 2018 Jul; 20(7):811-822. PMID: 29941929.
    View in: PubMed
  6. Nipp RD, El-Jawahri A, D'Arpino SM, Chan A, Fuh CX, Johnson PC, Lage DE, Wong RL, Pirl WF, Traeger L, Cashavelly BJ, Jackson VA, Ryan DP, Hochberg EP, Temel JS, Greer JA. Symptoms of posttraumatic stress disorder among hospitalized patients with cancer. Cancer. 2018 Aug; 124(16):3445-3453. PMID: 29905935.
    View in: PubMed
  7. Hong TS, Ryan DP. Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer-The New Standard of Care? JAMA Oncol. 2018 Jun 14; 4(6):e180070. PMID: 29566113.
    View in: PubMed
  8. Keane FK, Wo JY, Ferrone CR, Clark JW, Blaszkowsky LS, Allen JN, Kwak EL, Ryan DP, Lillemoe KD, Fernandez-Del Castillo C, Hong TS. Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma. Am J Clin Oncol. 2018 Jun; 41(6):607-612. PMID: 27740973.
    View in: PubMed
  9. Kamran SC, Clark JW, Zheng H, Borger DR, Blaszkowsky LS, Allen JN, Kwak EL, Wo JY, Parikh AR, Nipp RD, Murphy JE, Goyal L, Zhu AX, Iafrate AJ, Corcoran RB, Ryan DP, Hong TS. Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysis. Cancer Med. 2018 May 17. PMID: 29771009.
    View in: PubMed
  10. McDuff SGR, Remillard KA, Zheng H, Raldow AC, Wo JY, Eyler CE, Drapek LC, Goyal L, Blaszkowsky LS, Clark JW, Allen JN, Parikh AR, Ryan DP, Ferrone CR, Tanabe KK, Wolfgang JA, Zhu AX, Hong TS. Liver reirradiation for patients with hepatocellular carcinoma and liver metastasis. Pract Radiat Oncol. 2018 Apr 26. PMID: 29937235.
    View in: PubMed
  11. Michelakos T, Pergolini I, Castillo CF, Honselmann KC, Cai L, Deshpande V, Wo JY, Ryan DP, Allen JN, Blaszkowsky LS, Clark JW, Murphy JE, Nipp RD, Parikh A, Qadan M, Warshaw AL, Hong TS, Lillemoe KD, Ferrone CR. Predictors of Resectability and Survival in Patients with Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment with FOLFIRINOX. Ann Surg. 2017 Dec 07. PMID: 29227344.
    View in: PubMed
  12. O'Reilly EM, Roach J, Miller P, Yu KH, Tjan C, Rosano M, Krause S, Avery W, Wolf J, Flaherty K, Nix D, Ryan DP. Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results. Oncologist. 2017 12; 22(12):1429-e139. PMID: 29158367.
    View in: PubMed
  13. Lage DE, Nipp RD, D'Arpino SM, Moran SM, Johnson PC, Wong RL, Pirl WF, Hochberg EP, Traeger LN, Jackson VA, Cashavelly BJ, Martinson HS, Greer JA, Ryan DP, Temel JS, El-Jawahri A. Predictors of Posthospital Transitions of Care in Patients With Advanced Cancer. J Clin Oncol. 2018 Jan 01; 36(1):76-82. PMID: 29068784.
    View in: PubMed
  14. Nipp RD, El-Jawahri A, Moran SM, D'Arpino SM, Johnson PC, Lage DE, Wong RL, Pirl WF, Traeger L, Lennes IT, Cashavelly BJ, Jackson VA, Greer JA, Ryan DP, Hochberg EP, Temel JS. The relationship between physical and psychological symptoms and health care utilization in hospitalized patients with advanced cancer. Cancer. 2017 Dec 01; 123(23):4720-4727. PMID: 29057450.
    View in: PubMed
  15. El-Jawahri A, Lau-Min K, Nipp RD, Greer JA, Traeger LN, Moran SM, D'Arpino SM, Hochberg EP, Jackson VA, Cashavelly BJ, Martinson HS, Ryan DP, Temel JS. Processes of code status transitions in hospitalized patients with advanced cancer. Cancer. 2017 Dec 15; 123(24):4895-4902. PMID: 28881383.
    View in: PubMed
  16. Miller CL, Taylor MS, Qadan M, Deshpande V, Worthington S, Smalley R, Collura C, Ryan DP, Allen JN, Blaszkowsky LS, Clark JW, Murphy JE, Parikh AR, Berger D, Tanabe KK, Lillemoe KD, Ferrone CR. Prognostic Significance of Surgical Margin Size After Neoadjuvant FOLFOX and/or FOLFIRI for Colorectal Liver Metastases. J Gastrointest Surg. 2017 Nov; 21(11):1831-1840. PMID: 28884391.
    View in: PubMed
  17. Hong TS, Wo JY, Borger DR, Yeap BY, McDonnell EI, Willers H, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Tanguturi S, Goyal L, Murphy JE, Wolfgang JA, Drapek LC, Arellano RS, Mamon HJ, Mullen JT, Tanabe KK, Ferrone CR, Ryan DP, Iafrate AJ, DeLaney TF, Zhu AX. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype. J Natl Cancer Inst. 2017 Sep 01; 109(9). PMID: 28954285.
    View in: PubMed
  18. Franses JW, Basar O, Kadayifci A, Yuksel O, Choz M, Kulkarni AS, Tai E, Vo KD, Arora KS, Desai N, Licausi JA, Toner M, Maheswaran S, Haber DA, Ryan DP, Brugge WR, Ting DT. Improved Detection of Circulating Epithelial Cells in Patients with Intraductal Papillary Mucinous Neoplasms. Oncologist. 2018 Jan; 23(1):121-127. PMID: 28860411.
    View in: PubMed
  19. Pergolini I, Morales-Oyarvide V, Mino-Kenudson M, Honselmann KC, Rosenbaum MW, Nahar S, Kem M, Ferrone CR, Lillemoe KD, Bardeesy N, Ryan DP, Thayer SP, Warshaw AL, Fernández-Del Castillo C, Liss AS. Tumor engraftment in patient-derived xenografts of pancreatic ductal adenocarcinoma is associated with adverse clinicopathological features and poor survival. PLoS One. 2017; 12(8):e0182855. PMID: 28854237.
    View in: PubMed
  20. Kishan AU, Voog JC, Wiseman J, Cook RR, Ancukiewicz M, Lee P, Ryan DP, Clark JW, Berger DL, Cusack JC, Wo JY, Hong TS. Standard fractionation external beam radiotherapy with and without intraoperative radiotherapy for locally recurrent rectal cancer: the role of local therapy in patients with a high competing risk of death from distant disease. Br J Radiol. 2017 Aug; 90(1076):20170134. PMID: 28613934.
    View in: PubMed
  21. Liu H, Naxerova K, Pinter M, Incio J, Lee H, Shigeta K, Ho WW, Crain JA, Jacobson A, Michelakos T, Dias-Santos D, Zanconato A, Hong TS, Clark JW, Murphy JE, Ryan DP, Deshpande V, Lillemoe KD, Fernandez-Del Castillo C, Downes M, Evans RM, Michaelson J, Ferrone CR, Boucher Y, Jain RK. Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2017 Oct 01; 23(19):5959-5969. PMID: 28600474.
    View in: PubMed
  22. Nipp RD, Greer JA, El-Jawahri A, Moran SM, Traeger L, Jacobs JM, Jacobsen JC, Gallagher ER, Park ER, Ryan DP, Jackson VA, Pirl WF, Temel JS. Coping and Prognostic Awareness in Patients With Advanced Cancer. J Clin Oncol. 2017 Aug 01; 35(22):2551-2557. PMID: 28574777.
    View in: PubMed
  23. Irwin KE, Park ER, Shin JA, Fields LE, Jacobs JM, Greer JA, Taylor JB, Taghian AG, Freudenreich O, Ryan DP, Pirl WF. Predictors of Disruptions in Breast Cancer Care for Individuals with Schizophrenia. Oncologist. 2017 11; 22(11):1374-1382. PMID: 28559411.
    View in: PubMed
  24. Rose B, Mitra D, Hong TS, Jee KW, Niemierko A, Drapek LN, Blaszkowsky LS, Allen JN, Murphy JE, Clark JW, Ryan DP, Wo JY. Irradiation of anatomically defined pelvic subsites and acute hematologic toxicity in anal cancer patients undergoing chemoradiation. Pract Radiat Oncol. 2017 Sep - Oct; 7(5):e291-e297. PMID: 28462895.
    View in: PubMed
  25. Mitra D, Hong TS, Horick N, Rose B, Drapek LN, Blaszkowsky LS, Allen JN, Kwak EL, Murphy JE, Clark JW, Ryan DP, Cusack JC, Bordeianou LG, Berger DL, Wo JY. Long-term outcomes and toxicities of a large cohort of anal cancer patients treated with dose-painted IMRT per RTOG 0529. Adv Radiat Oncol. 2017 Apr-Jun; 2(2):110-117. PMID: 28740921.
    View in: PubMed
  26. Nipp RD, Zanconato A, Zheng H, Ferrone CR, Lillemoe KD, Wo JY, Hong TS, Clark JW, Ryan DP, Fernández-Del Castillo C. Predictors of Early Mortality After Surgical Resection of Pancreatic Adenocarcinoma in the Era of Neoadjuvant Treatment. Pancreas. 2017 02; 46(2):183-189. PMID: 27846142.
    View in: PubMed
  27. Kalinich M, Bhan I, Kwan TT, Miyamoto DT, Javaid S, LiCausi JA, Milner JD, Hong X, Goyal L, Sil S, Choz M, Ho U, Kapur R, Muzikansky A, Zhang H, Weitz DA, Sequist LV, Ryan DP, Chung RT, Zhu AX, Isselbacher KJ, Ting DT, Toner M, Maheswaran S, Haber DA. An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma. Proc Natl Acad Sci U S A. 2017 01 31; 114(5):1123-1128. PMID: 28096363.
    View in: PubMed
  28. Goyal L, Saha SK, Liu LY, Siravegna G, Leshchiner I, Ahronian LG, Lennerz JK, Vu P, Deshpande V, Kambadakone A, Mussolin B, Reyes S, Henderson L, Sun JE, Van Seventer EE, Gurski JM, Baltschukat S, Schacher-Engstler B, Barys L, Stamm C, Furet P, Ryan DP, Stone JR, Iafrate AJ, Getz G, Porta DG, Tiedt R, Bardelli A, Juric D, Corcoran RB, Bardeesy N, Zhu AX. Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma. Cancer Discov. 2017 03; 7(3):252-263. PMID: 28034880.
    View in: PubMed
  29. Temel JS, Greer JA, El-Jawahri A, Pirl WF, Park ER, Jackson VA, Back AL, Kamdar M, Jacobsen J, Chittenden EH, Rinaldi SP, Gallagher ER, Eusebio JR, Li Z, Muzikansky A, Ryan DP. Effects of Early Integrated Palliative Care in Patients With Lung and GI Cancer: A Randomized Clinical Trial. J Clin Oncol. 2017 Mar 10; 35(8):834-841. PMID: 28029308.
    View in: PubMed
  30. El-Jawahri A, Moran SM, D'Arpino S, Johnson C, Lage DE, Wong R, Xiao Y, VanDusen H, Pirl WF, Traeger L, Lennes IT, Cashavelly BJ, Martinson HS, Jackson VA, Greer JA, Ryan DP, Hochberg EP, Temel JS. Symptom burden to predict health care utilization in hospitalized patients with incurable cancer. J Clin Oncol. 2016 Oct 09; 34(26_suppl):98. PMID: 28156457.
    View in: PubMed
  31. Jackson VA, Greer JA, Pirl WF, Park ER, Back A, Muzikansky A, Kamdar M, Rinaldi S, Jacobsen J, Fishbein J, Eusebio J, VanDusen H, Nipp RD, Ryan DP, Temel JS. Effect of early integrated palliative care on family caregivers (FC) outcomes for patients with gastrointestinal and lung cancer. J Clin Oncol. 2016 Oct 09; 34(26_suppl):234. PMID: 28156551.
    View in: PubMed
  32. Ryan DP, Hong TS. Understanding the Paradigm Shift in Pancreatic Cancer. J Oncol Pract. 2016 10; 12(10):926-927. PMID: 27858558.
    View in: PubMed
  33. Schoenfeld JD, Wo JY, Mamon HJ, Kwak EL, Mullen JT, Enzinger PZ, Blaskowsky LS, Ryan DP, Hong TS. The Impact of Positive Margins on Outcome Among Patients With Gastric Cancer Treated With Radiation. Am J Clin Oncol. 2016 06; 39(3):243-7. PMID: 24577163.
    View in: PubMed
  34. Almhanna K, Kalebic T, Cruz C, Faris JE, Ryan DP, Jung J, Wyant T, Fasanmade AA, Messersmith W, Rodon J. Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody-Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies. Clin Cancer Res. 2016 Oct 15; 22(20):5049-5057. PMID: 27178743.
    View in: PubMed
  35. Patel SA, Ryan DP, Hong TS. Combined Modality Therapy for Rectal Cancer. Cancer J. 2016 May-Jun; 22(3):211-7. PMID: 27341601.
    View in: PubMed
  36. Lennes IT, Bohlen N, Park ER, Mort E, Burke D, Ryan DP. Chemotherapy Errors: A Call for a Standardized Approach to Measurement and Reporting. J Oncol Pract. 2016 Apr; 12(4):e495-501. PMID: 26957639.
    View in: PubMed
  37. Muralidhar V, Nipp RD, Ryan DP, Hong TS, Nguyen PL, Wo JY. Association Between Very Small Tumor Size and Increased Cancer-Specific Mortality in Node-Positive Colon Cancer. Dis Colon Rectum. 2016 Mar; 59(3):187-93. PMID: 26855392.
    View in: PubMed
  38. Eusebio J, Bohlen N, Ruddy M, Ryan DP. Characterization of unplanned 30-day medical oncology readmissions after discharge at an academic medical center with a comprehensive cancer center. J Clin Oncol. 2016 Mar; 34(7_suppl):269. PMID: 28152889.
    View in: PubMed
  39. Hong TS, Wo JY, Yeap BY, Ben-Josef E, McDonnell EI, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Goyal L, Murphy JE, Javle MM, Wolfgang JA, Drapek LC, Arellano RS, Mamon HJ, Mullen JT, Yoon SS, Tanabe KK, Ferrone CR, Ryan DP, DeLaney TF, Crane CH, Zhu AX. Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Clin Oncol. 2016 Feb 10; 34(5):460-8. PMID: 26668346; PMCID: PMC4872014 [Available on 10/10/16].
  40. El-Jawahri A, Pirl WF, Traeger L, Kumar P, Ryan DP, Lennes IT, Cashavelly BJ, Martinson HS, VanDusen H, Hochberg EP, Jackson VA, Greer JA, Temel JS, Nipp RD. Symptom burden in hospitalized patients with advanced cancer. J Clin Oncol. 2015 Oct 10; 33(29_suppl):100. PMID: 28148090.
    View in: PubMed
  41. Kwak EL, Ahronian LG, Siravegna G, Mussolin B, Borger DR, Godfrey JT, Jessop NA, Clark JW, Blaszkowsky LS, Ryan DP, Lennerz JK, Iafrate AJ, Bardelli A, Hong TS, Corcoran RB. Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer. Cancer Discov. 2015 12; 5(12):1271-81. PMID: 26432108.
    View in: PubMed
  42. Corcoran RB, Atreya CE, Falchook GS, Kwak EL, Ryan DP, Bendell JC, Hamid O, Messersmith WA, Daud A, Kurzrock R, Pierobon M, Sun P, Cunningham E, Little S, Orford K, Motwani M, Bai Y, Patel K, Venook AP, Kopetz S. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. J Clin Oncol. 2015 Dec 01; 33(34):4023-31. PMID: 26392102.
    View in: PubMed
  43. Allegra CJ, Yothers G, O'Connell MJ, Beart RW, Wozniak TF, Pitot HC, Shields AF, Landry JC, Ryan DP, Arora A, Evans LS, Bahary N, Soori G, Eakle JF, Robertson JM, Moore DF, Mullane MR, Marchello BT, Ward PJ, Sharif S, Roh MS, Wolmark N. Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial. J Natl Cancer Inst. 2015 Nov; 107(11). PMID: 26374429; PMCID: PMC4849360 [Available on 11/01/16].
  44. Goyal L, Govindan A, Sheth RA, Nardi V, Blaszkowsky LS, Faris JE, Clark JW, Ryan DP, Kwak EL, Allen JN, Murphy JE, Saha SK, Hong TS, Wo JY, Ferrone CR, Tanabe KK, Chong DQ, Deshpande V, Borger DR, Iafrate AJ, Bardeesy N, Zheng H, Zhu AX. Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma. Oncologist. 2015 Sep; 20(9):1019-27. PMID: 26245674; PMCID: PMC4571807.
  45. Benson AB, Venook AP, Bekaii-Saab T, Chan E, Chen YJ, Cooper HS, Engstrom PF, Enzinger PC, Fenton MJ, Fuchs CS, Grem JL, Grothey A, Hochster HS, Hunt S, Kamel A, Kirilcuk N, Leong LA, Lin E, Messersmith WA, Mulcahy MF, Murphy JD, Nurkin S, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Freedman-Cass D. Rectal Cancer, Version 2.2015. J Natl Compr Canc Netw. 2015 Jun; 13(6):719-28; quiz 728. PMID: 26085388.
    View in: PubMed
  46. Nipp RD, Ryan DP. Predicting a response to FOLFIRINOX in pancreatic cancer. J Natl Cancer Inst. 2015 Aug; 107(8). PMID: 26025325; PMCID: PMC4609560.
  47. Hong TS, Ryan DP. Adjuvant Chemotherapy for Locally Advanced Rectal Cancer: Is It a Given? J Clin Oncol. 2015 Jun 10; 33(17):1878-80. PMID: 25940719.
    View in: PubMed
  48. Nipp RD, Ryan DP. Should FOLFOXIRI plus bevacizumab Be the standard first-line therapy in metastatic colorectal cancer? Oncologist. 2015 Mar; 20(3):236-8. PMID: 25660156; PMCID: PMC4350810.
  49. Chan CH, Cusack JC, Ryan DP. A critical look at local-regional management of peritoneal metastasis. Hematol Oncol Clin North Am. 2015 Feb; 29(1):153-8. PMID: 25475577.
    View in: PubMed
  50. Percac-Lima S, Cronin PR, Ryan DP, Chabner BA, Daly EA, Kimball AB. Patient navigation based on predictive modeling decreases no-show rates in cancer care. Cancer. 2015 May 15; 121(10):1662-70. PMID: 25585595.
    View in: PubMed
  51. Cercek A, Cusack JC, Ryan DP. Treatment of peritoneal carcinomatosis of colorectal origin. Am Soc Clin Oncol Educ Book. 2015; e208-11. PMID: 25993175.
    View in: PubMed
  52. Ferrone CR, Marchegiani G, Hong TS, Ryan DP, Deshpande V, McDonnell EI, Sabbatino F, Santos DD, Allen JN, Blaszkowsky LS, Clark JW, Faris JE, Goyal L, Kwak EL, Murphy JE, Ting DT, Wo JY, Zhu AX, Warshaw AL, Lillemoe KD, Fernández-del Castillo C. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg. 2015 Jan; 261(1):12-7. PMID: 25599322; PMCID: PMC4349683.
  53. Borad MJ, Reddy SG, Bahary N, Uronis HE, Sigal D, Cohn AL, Schelman WR, Stephenson J, Chiorean EG, Rosen PJ, Ulrich B, Dragovich T, Del Prete SA, Rarick M, Eng C, Kroll S, Ryan DP. Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer. J Clin Oncol. 2015 May 01; 33(13):1475-81. PMID: 25512461.
    View in: PubMed
  54. Goldman J, Eckhardt SG, Borad MJ, Curtis KK, Hidalgo M, Calvo E, Ryan DP, Wirth LJ, Parikh A, Partyka J, Faessel H, Gangolli E, Stewart S, Rosen LS, Bowles DW. Phase I dose-escalation trial of the oral investigational Hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors. Clin Cancer Res. 2015 Mar 01; 21(5):1002-9. PMID: 25501576.
    View in: PubMed
  55. Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014 11 27; 371(22):2140-1. PMID: 25427123.
    View in: PubMed
  56. Mirabeau-Beale K, Hong TS, Niemierko A, Ancukiewicz M, Blaszkowsky LS, Crowley EM, Cusack JC, Drapek LC, Kovalchuk N, Markowski M, Napolitano B, Nyamwanda J, Ryan DP, Wolfgang J, Kachnic LA, Wo JY. Clinical and treatment factors associated with vaginal stenosis after definitive chemoradiation for anal canal cancer. Pract Radiat Oncol. 2015 May-Jun; 5(3):e113-8. PMID: 25424587.
    View in: PubMed
  57. Rostamnjad L, Diviak M, Ryan DP, Blouin GC. Justification of more expensive antiemetic use with FOLFOX at an ambulatory cancer center. J Clin Oncol. 2014 Oct 20; 32(30_suppl):27. PMID: 28141436.
    View in: PubMed
  58. Zenteno Langle AC, Duk M, Levy Carlis A, Bloom M, Souza E, Levi R, Ryan DP. Modeling and improving chemotherapy patient flow. J Clin Oncol. 2014 Oct 20; 32(30_suppl):175. PMID: 28141203.
    View in: PubMed
  59. Bohlen N, Ryan DP. Improving safety culture at a large AMC. J Clin Oncol. 2014 Oct 20; 32(30_suppl):105. PMID: 28141396.
    View in: PubMed
  60. Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014 Sep 11; 371(11):1039-49. PMID: 25207767.
    View in: PubMed
  61. Abtahian F, Hawkins BM, Ryan DP, Cefalo P, Nasser NJ, MacKay C, Jaff MR, Weinberg I. Inferior vena cava filter usage, complications, and retrieval rate in cancer patients. Am J Med. 2014 Nov; 127(11):1111-7. PMID: 24997415.
    View in: PubMed
  62. Benson AB, Venook AP, Bekaii-Saab T, Chan E, Chen YJ, Cooper HS, Engstrom PF, Enzinger PC, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, Messersmith W, Mulcahy MF, Murphy JD, Nurkin S, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Freedman-Cass DA. Colon cancer, version 3.2014. J Natl Compr Canc Netw. 2014 Jul; 12(7):1028-59. PMID: 24994923.
    View in: PubMed
  63. Ting DT, Ryan DP. The wide gulf between stage III and stage IV colon cancer. Lancet Oncol. 2014 Jul; 15(8):785-6. PMID: 24928084.
    View in: PubMed
  64. Hong TS, Ryan DP, Borger DR, Blaszkowsky LS, Yeap BY, Ancukiewicz M, Deshpande V, Shinagare S, Wo JY, Boucher Y, Wadlow RC, Kwak EL, Allen JN, Clark JW, Zhu AX, Ferrone CR, Mamon HJ, Adams J, Winrich B, Grillo T, Jain RK, DeLaney TF, Fernandez-del Castillo C, Duda DG. A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma. Int J Radiat Oncol Biol Phys. 2014 Jul 15; 89(4):830-8. PMID: 24867540.
    View in: PubMed
  65. O'Connell MJ, Colangelo LH, Beart RW, Petrelli NJ, Allegra CJ, Sharif S, Pitot HC, Shields AF, Landry JC, Ryan DP, Parda DS, Mohiuddin M, Arora A, Evans LS, Bahary N, Soori GS, Eakle J, Robertson JM, Moore DF, Mullane MR, Marchello BT, Ward PJ, Wozniak TF, Roh MS, Yothers G, Wolmark N. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol. 2014 Jun 20; 32(18):1927-34. PMID: 24799484; PMCID: PMC4050205.
  66. Schapira L, Blaszkowsky LS, Cashavelly BJ, Kim CY, Riley JP, Wold MC, Ryan DP, Penson RT. Caring for one of our own. Oncologist. 2014 May; 19(5):545-9. PMID: 24721818; PMCID: PMC4012977.
  67. Russo AL, Ryan DP, Borger DR, Wo JY, Szymonifka J, Liang WY, Kwak EL, Blaszkowsky LS, Clark JW, Allen JN, Zhu AX, Berger DL, Cusack JC, Mamon HJ, Haigis KM, Hong TS. Mutational and clinical predictors of pathologic complete response in the treatment of locally advanced rectal cancer. J Gastrointest Cancer. 2014 Mar; 45(1):34-9. PMID: 24006244; PMCID: PMC4361942.
  68. Russo AL, Borger DR, Szymonifka J, Ryan DP, Wo JY, Blaszkowsky LS, Kwak EL, Allen JN, Wadlow RC, Zhu AX, Murphy JE, Faris JE, Dias-Santagata D, Haigis KM, Ellisen LW, Iafrate AJ, Hong TS. Mutational analysis and clinical correlation of metastatic colorectal cancer. Cancer. 2014 May 15; 120(10):1482-90. PMID: 24500602; PMCID: PMC4327902.
  69. Borger DR, Goyal L, Yau T, Poon RT, Ancukiewicz M, Deshpande V, Christiani DC, Liebman HM, Yang H, Kim H, Yen K, Faris JE, Iafrate AJ, Kwak EL, Clark JW, Allen JN, Blaszkowsky LS, Murphy JE, Saha SK, Hong TS, Wo JY, Ferrone CR, Tanabe KK, Bardeesy N, Straley KS, Agresta S, Schenkein DP, Ellisen LW, Ryan DP, Zhu AX. Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma. Clin Cancer Res. 2014 Apr 01; 20(7):1884-90. PMID: 24478380; PMCID: PMC4107454.
  70. Goyal L, Supko JG, Berlin J, Blaszkowsky LS, Carpenter A, Heuman DM, Hilderbrand SL, Stuart KE, Cotler S, Senzer NN, Chan E, Berg CL, Clark JW, Hezel AF, Ryan DP, Zhu AX. Phase 1 study of N(1),N(11)-diethylnorspermine (DENSPM) in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2013 Dec; 72(6):1305-14. PMID: 24121453.
    View in: PubMed
  71. Hong TS, DeLaney TF, Mamon HJ, Willett CG, Yeap BY, Niemierko A, Wolfgang JA, Lu HM, Adams J, Weyman EA, Arellano RS, Blaszkowsky LS, Allen JN, Tanabe KK, Ryan DP, Zhu AX. A prospective feasibility study of respiratory-gated proton beam therapy for liver tumors. Pract Radiat Oncol. 2014 Sep-Oct; 4(5):316-322. PMID: 25194100.
    View in: PubMed
  72. Wo JY, Mamon HJ, Ferrone CR, Ryan DP, Blaszkowsky LS, Kwak EL, Tseng YD, Napolitano BN, Ancukiewicz M, Swanson RS, Lillemoe KD, Fernandez-del Castillo C, Hong TS. Phase I study of neoadjuvant accelerated short course radiation therapy with photons and capecitabine for resectable pancreatic cancer. Radiother Oncol. 2014 Jan; 110(1):160-4. PMID: 24231241.
    View in: PubMed
  73. Chio C, Kim EB, Ryan DP. Evaluating adherence to off-label policy at an academic outpatient cancer center and assessing reimbursement of high-cost drugs. J Clin Oncol. 2013 Nov; 31(31_suppl):61. PMID: 28136485.
    View in: PubMed
  74. Bohlen N, Rosato E, Fitzgerald E, Cashavelly BJ, Lafleur K, Ahmed S, Burke D, Ryan DP. Chemotherapy order review, activation, preparation, and administration redesign at a large academic cancer center. J Clin Oncol. 2013 Nov; 31(31_suppl):221. PMID: 28136345.
    View in: PubMed
  75. Mullen JT, Ryan DP. Neoadjuvant chemotherapy for gastric cancer: what are we trying to accomplish? Ann Surg Oncol. 2014 Jan; 21(1):13-5. PMID: 24046112.
    View in: PubMed
  76. Cai S, Hong TS, Goldberg SI, Fernandez-del Castillo C, Thayer SP, Ferrone CR, Ryan DP, Blaszkowsky LS, Kwak EL, Willett CG, Lillemoe KD, Warshaw AL, Wo JY. Updated long-term outcomes and prognostic factors for patients with unresectable locally advanced pancreatic cancer treated with intraoperative radiotherapy at the Massachusetts General Hospital, 1978 to 2010. Cancer. 2013 Dec 01; 119(23):4196-204. PMID: 24006012; PMCID: PMC4403862.
  77. Faris JE, Ryan DP. Controversy and consensus on the management of patients with pseudomyxoma peritonei. Curr Treat Options Oncol. 2013 Sep; 14(3):365-73. PMID: 23934509.
    View in: PubMed
  78. Wo JY, Childs SK, Szymonifka J, Mamon HJ, Ryan DP, Blaszkowsky LS, Kwak EL, Ferrone CR, Allen JN, Zhu AX, Wolpin BM, Chan JA, Abrams TA, McCleary NJ, Fernandez-Del Castillo C, Hong TS. Delaying chemoradiation until after completion of adjuvant chemotherapy for pancreatic cancer may not impact local control. Pract Radiat Oncol. 2014 Mar-Apr; 4(2):e117-e123. PMID: 24890357.
    View in: PubMed
  79. Ng K, Tabernero J, Hwang J, Bajetta E, Sharma S, Del Prete SA, Arrowsmith ER, Ryan DP, Sedova M, Jin J, Malek K, Fuchs CS. Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens. Clin Cancer Res. 2013 Jul 15; 19(14):3987-95. PMID: 23743569; PMCID: PMC3725595.
  80. Chan JA, Blaszkowsky L, Stuart K, Zhu AX, Allen J, Wadlow R, Ryan DP, Meyerhardt J, Gonzalez M, Regan E, Zheng H, Kulke MH. A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor. Cancer. 2013 Sep 01; 119(17):3212-8. PMID: 23733618; PMCID: PMC4308727.
  81. Faris JE, Blaszkowsky LS, McDermott S, Guimaraes AR, Szymonifka J, Huynh MA, Ferrone CR, Wargo JA, Allen JN, Dias LE, Kwak EL, Lillemoe KD, Thayer SP, Murphy JE, Zhu AX, Sahani DV, Wo JY, Clark JW, Fernandez-del Castillo C, Ryan DP, Hong TS. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Oncologist. 2013; 18(5):543-8. PMID: 23657686; PMCID: PMC3662845.
  82. Benson AB, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Engstrom PF, Enzinger PC, Fakih MG, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W, Sofocleous CT, Venook AP, Willett CG, Gregory KM, Freedman-Cass DA. Localized colon cancer, version 3.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2013 May 01; 11(5):519-28. PMID: 23667203.
    View in: PubMed
  83. Rubinson DA, Hochster HS, Ryan DP, Wolpin BM, McCleary NJ, Abrams TA, Chan JA, Iqbal S, Lenz HJ, Lim D, Rose J, Bekaii-Saab T, Chen HX, Fuchs CS, Ng K. Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients. Invest New Drugs. 2014 Feb; 32(1):113-22. PMID: 23568716; PMCID: PMC3775976.
  84. Konstantinidis IT, Warshaw AL, Allen JN, Blaszkowsky LS, Castillo CF, Deshpande V, Hong TS, Kwak EL, Lauwers GY, Ryan DP, Wargo JA, Lillemoe KD, Ferrone CR. Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection? Ann Surg. 2013 Apr; 257(4):731-6. PMID: 22968073.
    View in: PubMed
  85. Lee MS, Mamon HJ, Hong TS, Choi NC, Fidias PM, Kwak EL, Meyerhardt JA, Ryan DP, Bueno R, Donahue DM, Jaklitsch MT, Lanuti M, Rattner DW, Fuchs CS, Enzinger PC. Preoperative cetuximab, irinotecan, cisplatin, and radiation therapy for patients with locally advanced esophageal cancer. Oncologist. 2013; 18(3):281-7. PMID: 23429739; PMCID: PMC3607524.
  86. Benson AB, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Engstrom PF, Enzinger PC, Fakih MG, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W, Sofocleous CT, Venook AP, Willett CG, Gregory KM, Freedman-Cass DA. Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2013 Feb 01; 11(2):141-52; quiz 152. PMID: 23411381.
    View in: PubMed
  87. Zhu AX, Ancukiewicz M, Supko JG, Sahani DV, Blaszkowsky LS, Meyerhardt JA, Abrams TA, McCleary NJ, Bhargava P, Muzikansky A, Sheehan S, Regan E, Vasudev E, Knowles M, Fuchs CS, Ryan DP, Jain RK, Duda DG. Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study. Clin Cancer Res. 2013 Mar 15; 19(6):1557-66. PMID: 23362324; PMCID: PMC3609423.
  88. Benson AB, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Engstrom PF, Enzinger PC, Fakih MG, Fuchs CS, Grem JL, Hunt S, Leong LA, Lin E, Martin MG, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W, Sofocleous CT, Venook AP, Willett CG, Freedman-Cass DA, Gregory KM. Rectal cancer. J Natl Compr Canc Netw. 2012 Dec 01; 10(12):1528-64. PMID: 23221790.
    View in: PubMed
  89. Phillips JG, Hong TS, Ryan DP. Multidisciplinary management of early-stage rectal cancer. J Natl Compr Canc Netw. 2012 Dec 01; 10(12):1577-85. PMID: 23221792.
    View in: PubMed
  90. Chin JY, Hong TS, Ryan DP. Mitomycin in anal cancer: still the standard of care. J Clin Oncol. 2012 Dec 10; 30(35):4297-301. PMID: 23150704.
    View in: PubMed
  91. McCleary NJ, Odejide O, Szymonifka J, Ryan D, Hezel A, Meyerhardt JA. Safety and effectiveness of oxaliplatin-based chemotherapy regimens in adults 75 years and older with colorectal cancer. Clin Colorectal Cancer. 2013 Mar; 12(1):62-9. PMID: 23102897; PMCID: PMC3802549.
  92. Chan JA, Ryan DP, Zhu AX, Abrams TA, Wolpin BM, Malinowski P, Regan EM, Fuchs CS, Kulke MH. Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors. Endocr Relat Cancer. 2012 Oct; 19(5):615-23. PMID: 22736724; PMCID: PMC4469068.
  93. Sugarbaker PH, Ryan DP. Cytoreductive surgery plus hyperthermic perioperative chemotherapy to treat peritoneal metastases from colorectal cancer: standard of care or an experimental approach? Lancet Oncol. 2012 Aug; 13(8):e362-9. PMID: 22846841.
    View in: PubMed
  94. Ryan DP. A partnership between the academic and the community. J Natl Compr Canc Netw. 2012 Aug; 10(8):919-21. PMID: 22878815.
    View in: PubMed
  95. Yu M, Ting DT, Stott SL, Wittner BS, Ozsolak F, Paul S, Ciciliano JC, Smas ME, Winokur D, Gilman AJ, Ulman MJ, Xega K, Contino G, Alagesan B, Brannigan BW, Milos PM, Ryan DP, Sequist LV, Bardeesy N, Ramaswamy S, Toner M, Maheswaran S, Haber DA. RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature. 2012 Jul 26; 487(7408):510-3. PMID: 22763454; PMCID: PMC3408856.
  96. Benson AB, Arnoletti JP, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Dilawari RA, Engstrom PF, Enzinger PC, Fakih MG, Fleshman JW, Fuchs CS, Grem JL, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W, Sofocleous CT, Venook AP, Willett C, Freedman-Cass DA. Anal Carcinoma, Version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012 Apr; 10(4):449-54. PMID: 22491045.
    View in: PubMed
  97. Chen RC, Mamon HJ, Ancukiewicz M, Killoran JH, Crowley EM, Blaszkowsky LS, Wo JY, Ryan DP, Hong TS. Dose--volume effects on patient-reported acute gastrointestinal symptoms during chemoradiation therapy for rectal cancer. Int J Radiat Oncol Biol Phys. 2012 Jul 15; 83(4):e513-7. PMID: 22436781.
    View in: PubMed
  98. Arvold ND, Willett CG, Fernandez-del Castillo C, Ryan DP, Ferrone CR, Clark JW, Blaszkowsky LS, Deshpande V, Niemierko A, Allen JN, Kwak EL, Wadlow RC, Zhu AX, Warshaw AL, Hong TS. Pancreatic neuroendocrine tumors with involved surgical margins: prognostic factors and the role of adjuvant radiotherapy. Int J Radiat Oncol Biol Phys. 2012 Jul 01; 83(3):e337-43. PMID: 22414286.
    View in: PubMed
  99. Faris JE, Ryan DP. Trees, forests, and other implications of a BRAF mutant gene signature in patients with BRAF wild-type disease. J Clin Oncol. 2012 Apr 20; 30(12):1255-7. PMID: 22393091.
    View in: PubMed
  100. Nardi V, Song Y, Santamaria-Barria JA, Cosper AK, Lam Q, Faber AC, Boland GM, Yeap BY, Bergethon K, Scialabba VL, Tsao H, Settleman J, Ryan DP, Borger DR, Bhan AK, Hoang MP, Iafrate AJ, Cusack JC, Engelman JA, Dias-Santagata D. Activation of PI3K signaling in Merkel cell carcinoma. Clin Cancer Res. 2012 Mar 01; 18(5):1227-36. PMID: 22261808; PMCID: PMC3912509.
  101. Wadlow RC, Hezel AF, Abrams TA, Blaszkowsky LS, Fuchs CS, Kulke MH, Kwak EL, Meyerhardt JA, Ryan DP, Szymonifka J, Wolpin BM, Zhu AX, Clark JW. Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab. Oncologist. 2012; 17(1):14. PMID: 22210091; PMCID: PMC3267814.
  102. Borger DR, Tanabe KK, Fan KC, Lopez HU, Fantin VR, Straley KS, Schenkein DP, Hezel AF, Ancukiewicz M, Liebman HM, Kwak EL, Clark JW, Ryan DP, Deshpande V, Dias-Santagata D, Ellisen LW, Zhu AX, Iafrate AJ. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist. 2012; 17(1):72-9. PMID: 22180306; PMCID: PMC3267826.
  103. Benson AB, Arnoletti JP, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Dilawari RA, Engstrom PF, Enzinger PC, Fleshman JW, Fuchs CS, Grem JL, Knol JA, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W, Sofocleous CT, Venook AP, Willett C. Colon cancer. J Natl Compr Canc Netw. 2011 Nov; 9(11):1238-90. PMID: 22056656.
    View in: PubMed
  104. Arvold ND, Ryan DP, Niemierko A, Blaszkowsky LS, Kwak EL, Wo JY, Allen JN, Clark JW, Wadlow RC, Zhu AX, Fernandez-Del Castillo C, Hong TS. Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer. Cancer. 2012 Jun 15; 118(12):3026-35. PMID: 22020923.
    View in: PubMed
  105. Ebi H, Corcoran RB, Singh A, Chen Z, Song Y, Lifshits E, Ryan DP, Meyerhardt JA, Benes C, Settleman J, Wong KK, Cantley LC, Engelman JA. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J Clin Invest. 2011 Nov; 121(11):4311-21. PMID: 21985784.
    View in: PubMed
  106. Faris JE, Arnott J, Zheng H, Ryan DP, Abrams TA, Blaszkowsky LS, Clark JW, Enzinger PC, Hezel AF, Ng K, Wolpin BM, Kwak EL. A phase 2 study of oral MKC-1, an inhibitor of importin-ß, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer. Invest New Drugs. 2012 Aug; 30(4):1614-20. PMID: 21800081; PMCID: PMC3670147.
  107. Wo JY, Mamon HJ, Ryan DP, Hong TS. T3N0 rectal cancer: radiation for all? Semin Radiat Oncol. 2011 Jul; 21(3):212-9. PMID: 21645866.
    View in: PubMed
  108. Alexander BM, Fernandez-Del Castillo C, Ryan DP, Kachnic LA, Hezel AF, Niemierko A, Willett CG, Kozak KR, Blaszkowsky LS, Clark JW, Warshaw AL, Hong TS. Intraductal papillary mucinous adenocarcinoma of the pancreas: clinical outcomes, prognostic factors, and the role of adjuvant therapy. Gastrointest Cancer Res. 2011 Jul; 4(4):116-21. PMID: 22368734; PMCID: PMC3283102.
  109. Wo JY, Ryan DP, Kulke MH, Hong TS. Radiation recall associated with insulin growth factor 1R antibody. Pract Radiat Oncol. 2011 Jul-Sep; 1(3):208-11. PMID: 24673952.
    View in: PubMed
  110. Zhu AX, Abrams TA, Miksad R, Blaszkowsky LS, Meyerhardt JA, Zheng H, Muzikansky A, Clark JW, Kwak EL, Schrag D, Jors KR, Fuchs CS, Iafrate AJ, Borger DR, Ryan DP. Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer. 2011 Nov 15; 117(22):5094-102. PMID: 21538343; PMCID: PMC3417818.
  111. Margalit DN, Mamon HJ, Ancukiewicz M, Kobayashi W, Ryan DP, Blaszkowsky LS, Clark J, Willett CG, Hong TS. Tolerability of combined modality therapy for rectal cancer in elderly patients aged 75 years and older. Int J Radiat Oncol Biol Phys. 2011 Dec 01; 81(5):e735-41. PMID: 21377289.
    View in: PubMed
  112. Kozyreva ON, Chi D, Clark JW, Wang H, Theall KP, Ryan DP, Zhu AX. A multicenter retrospective study on clinical characteristics, treatment patterns, and outcome in elderly patients with hepatocellular carcinoma. Oncologist. 2011; 16(3):310-8. PMID: 21349948; PMCID: PMC3228108.
  113. Goldberg RM, Ryan DP. Scan? Cure? Sure! Oncologist. 2011; 16(2):254-6. PMID: 21349952; PMCID: PMC3228087.
  114. Kachnic LA, Tsai HK, Coen JJ, Blaszkowsky LS, Hartshorn K, Kwak EL, Willins JD, Ryan DP, Hong TS. Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy. Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):153-8. PMID: 21095071.
    View in: PubMed
  115. Zhu AX, Duda DG, Ancukiewicz M, di Tomaso E, Clark JW, Miksad R, Fuchs CS, Ryan DP, Jain RK. Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: kinetics and potential biomarker value. Clin Cancer Res. 2011 Feb 15; 17(4):918-27. PMID: 20843836; PMCID: PMC3023846.
  116. Murphy JE, Ryan DP. American Society of Clinical Oncology 2010 colorectal update. Expert Rev Anticancer Ther. 2010 Sep; 10(9):1371-3. PMID: 20836671.
    View in: PubMed
  117. Wadlow RC, Ryan DP. The role of targeted agents in preoperative chemoradiation for rectal cancer. Cancer. 2010 Aug 01; 116(15):3537-48. PMID: 20564106.
    View in: PubMed
  118. Ryan DP, Engelman JA, Ferrone CR, Sahani DV, Lisovsky M. Case records of the Massachusetts General Hospital. Case 19-2010. A 35-year-old man with adenocarcinoma of the cecum. N Engl J Med. 2010 Jun 24; 362(25):2411-9. PMID: 20573930; PMCID: PMC3695632.
  119. Hong TS, Ryan DP, Blaszkowsky LS, Mamon HJ, Kwak EL, Mino-Kenudson M, Adams J, Yeap B, Winrich B, DeLaney TF, Fernandez-Del Castillo C. Phase I study of preoperative short-course chemoradiation with proton beam therapy and capecitabine for resectable pancreatic ductal adenocarcinoma of the head. Int J Radiat Oncol Biol Phys. 2011 Jan 01; 79(1):151-7. PMID: 20421151.
    View in: PubMed
  120. Engstrom PF, Arnoletti JP, Benson AB, Berlin JD, Berry JM, Chen YJ, Choti MA, Cooper HS, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J, Fuchs C, Grem JL, Knol JA, Leong LA, Lin E, Mulcahy MF, Rohren E, Ryan DP, Saltz L, Shibata D, Skibber JM, Small W, Sofocleous C, Thomas J, Venook AP, Willett C. NCCN clinical practice guidelines in oncology. Anal carcinoma. J Natl Compr Canc Netw. 2010 Jan; 8(1):106-20. PMID: 20064293.
    View in: PubMed
  121. Zhu AX, Meyerhardt JA, Blaszkowsky LS, Kambadakone AR, Muzikansky A, Zheng H, Clark JW, Abrams TA, Chan JA, Enzinger PC, Bhargava P, Kwak EL, Allen JN, Jain SR, Stuart K, Horgan K, Sheehan S, Fuchs CS, Ryan DP, Sahani DV. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol. 2010 Jan; 11(1):48-54. PMID: 19932054.
    View in: PubMed
  122. Miyamoto DT, Mamon HJ, Ryan DP, Willett CG, Ancukiewicz M, Kobayashi WK, Blaszkowsky L, Fernandez-del Castillo C, Hong TS. Outcomes and tolerability of chemoradiation therapy for pancreatic cancer patients aged 75 years or older. Int J Radiat Oncol Biol Phys. 2010 Jul 15; 77(4):1171-7. PMID: 19800182.
    View in: PubMed
  123. Engstrom PF, Arnoletti JP, Benson AB, Chen YJ, Choti MA, Cooper HS, Covey A, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Lin E, Mulcahy MF, Rao S, Ryan DP, Saltz L, Shibata D, Skibber JM, Sofocleous C, Thomas J, Venook AP, Willett C. NCCN Clinical Practice Guidelines in Oncology: colon cancer. J Natl Compr Canc Netw. 2009 Sep; 7(8):778-831. PMID: 19755046.
    View in: PubMed
  124. Engstrom PF, Arnoletti JP, Benson AB, Chen YJ, Choti MA, Cooper HS, Covey A, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Lin E, Mulcahy MF, Rao S, Ryan DP, Saltz L, Shibata D, Skibber JM, Sofocleous C, Thomas J, Venook AP, Willett C. NCCN Clinical Practice Guidelines in Oncology: rectal cancer. J Natl Compr Canc Netw. 2009 Sep; 7(8):838-81. PMID: 19755047.
    View in: PubMed
  125. Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhwani V, Blaszkowsky LS, Yoon SS, Lahdenranta J, Bhargava P, Meyerhardt J, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger PC, Fuchs CS, Ryan DP, Jain RK. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol. 2009 Jun 20; 27(18):3027-35. PMID: 19470923; PMCID: PMC2702235.
  126. Zawacki WJ, Walker TG, DeVasher E, Halpern EF, Waltman AC, Wicky ST, Ryan DP, Kalva SP. Wound dehiscence or failure to heal following venous access port placement in patients receiving bevacizumab therapy. J Vasc Interv Radiol. 2009 May; 20(5):624-7; quiz 571. PMID: 19328717.
    View in: PubMed
  127. Goulart BH, Clark JW, Lauwers GY, Ryan DP, Grenon N, Muzikansky A, Zhu AX. Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis. J Hematol Oncol. 2009 Mar 16; 2:13. PMID: 19291303; PMCID: PMC2663565.
  128. Kulke MH, Hornick JL, Frauenhoffer C, Hooshmand S, Ryan DP, Enzinger PC, Meyerhardt JA, Clark JW, Stuart K, Fuchs CS, Redston MS. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res. 2009 Jan 01; 15(1):338-45. PMID: 19118063; PMCID: PMC3100724.
  129. Zhu AX, Ready N, Clark JW, Safran H, Amato A, Salem N, Pace S, He X, Zvereva N, Lynch TJ, Ryan DP, Supko JG. Phase I and pharmacokinetic study of gimatecan given orally once a week for 3 of 4 weeks in patients with advanced solid tumors. Clin Cancer Res. 2009 Jan 01; 15(1):374-81. PMID: 19118068.
    View in: PubMed
  130. Wolpin BM, Hezel AF, Abrams T, Blaszkowsky LS, Meyerhardt JA, Chan JA, Enzinger PC, Allen B, Clark JW, Ryan DP, Fuchs CS. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol. 2009 Jan 10; 27(2):193-8. PMID: 19047305; PMCID: PMC2645085.
  131. Wright FC, Gagliardi AR, Law CH, Last LD, Klevan AE, Hongjinda S, Stitt LW, Klar N, Ryan DP, Smith AJ. A randomized controlled trial to improve lymph node assessment in stage II colon cancer. Arch Surg. 2008 Nov; 143(11):1050-5; discussion 1055. PMID: 19015462.
    View in: PubMed
  132. Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, Li JZ, Baum CM, Fuchs CS. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol. 2008 Jul 10; 26(20):3403-10. PMID: 18612155.
    View in: PubMed
  133. Asomaning K, Reid AE, Zhou W, Heist RS, Zhai R, Su L, Kwak EL, Blaszkowsky L, Zhu AX, Ryan DP, Christiani DC, Liu G. MDM2 promoter polymorphism and pancreatic cancer risk and prognosis. Clin Cancer Res. 2008 Jun 15; 14(12):4010-5. PMID: 18559624.
    View in: PubMed
  134. Kozuch PS, Rocha-Lima CM, Dragovich T, Hochster H, O'Neil BH, Atiq OT, Pipas JM, Ryan DP, Lenz HJ. Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: results from a randomized phase II study. J Clin Oncol. 2008 May 10; 26(14):2320-6. PMID: 18467723.
    View in: PubMed
  135. Crippa S, Domínguez I, Rodríguez JR, Razo O, Thayer SP, Ryan DP, Warshaw AL, Fernández-del Castillo C. Quality of life in pancreatic cancer: analysis by stage and treatment. J Gastrointest Surg. 2008 May; 12(5):783-93; discussion 793-4. PMID: 18317851; PMCID: PMC3806099.
  136. Wheatley-Price P, Asomaning K, Reid A, Zhai R, Su L, Zhou W, Zhu A, Ryan DP, Christiani DC, Liu G. Myeloperoxidase and superoxide dismutase polymorphisms are associated with an increased risk of developing pancreatic adenocarcinoma. Cancer. 2008 Mar 01; 112(5):1037-42. PMID: 18205184.
    View in: PubMed
  137. Kachnic LA, Hong TS, Ryan DP. Rectal cancer at the crossroads: the dilemma of clinically staged T3, N0, M0 disease. J Clin Oncol. 2008 Jan 20; 26(3):350-1. PMID: 18202407.
    View in: PubMed
  138. Zuckerman DS, Ryan DP. Adjuvant therapy for pancreatic cancer: a review. Cancer. 2008 Jan 15; 112(2):243-9. PMID: 18050292.
    View in: PubMed
  139. Sykes DB, Ting DT, Barbie DA, Chen YB, Deangelo DJ, and Ryan DP. Hematology-Oncology. Ed Mark Sabatine. Pocket Medicine. 2008.
  140. Ryan DP and Mamon H. Management of Locally Advanced Pancreatic Cancer. UpToDate. 2008; www.uptodate.com.
  141. Ryan DP. Adjuvant Therapy for Pancreatic Cancer. UpToDate. 2008; www.uptodate.com.
  142. Ryan DP and Willett CG. Classification and Epidemiology of Anal Cancer. UpToDate. 2008; www.uptodate.com.
  143. Ryan DP. Colon Cancer. Eds Chabner BA, Lynch TJ, and Longo DL. Harrison's Manual of Oncology. 2008.
  144. Ryan DP and Willett CG. Clinical Features, Staging, and Treatment of Anal Cancer. UpToDate. 2008; www.uptodate.com.
  145. Ryan DP. Chemotherapy for Advanced Pancreatic Cancer. UpToDate. 2008; www.uptodate.com.
  146. Kulke MH, Blaszkowsky LS, Ryan DP, Clark JW, Meyerhardt JA, Zhu AX, Enzinger PC, Kwak EL, Muzikansky A, Lawrence C, Fuchs CS. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol. 2007 Oct 20; 25(30):4787-92. PMID: 17947726.
    View in: PubMed
  147. Zhu AX, Stuart K, Blaszkowsky LS, Muzikansky A, Reitberg DP, Clark JW, Enzinger PC, Bhargava P, Meyerhardt JA, Horgan K, Fuchs CS, Ryan DP. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer. 2007 Aug 01; 110(3):581-9. PMID: 17583545.
    View in: PubMed
  148. Meyerhardt JA, Zhu AX, Stuart K, Ryan DP, Blaszkowsky L, Lehman N, Earle CC, Kulke MH, Bhargava P, Fuchs CS. Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer. Dig Dis Sci. 2008 Feb; 53(2):564-70. PMID: 17597402.
    View in: PubMed
  149. Kozak KR, Kachnic LA, Adams J, Crowley EM, Alexander BM, Mamon HJ, Fernandez-Del Castillo C, Ryan DP, DeLaney TF, Hong TS. Dosimetric feasibility of hypofractionated proton radiotherapy for neoadjuvant pancreatic cancer treatment. Int J Radiat Oncol Biol Phys. 2007 Aug 01; 68(5):1557-66. PMID: 17544599.
    View in: PubMed
  150. Hezel AF, Ryan DP. Emerging therapies for colorectal cancer. Expert Opin Investig Drugs. 2007 Jun; 16(6):867-76. PMID: 17501698.
    View in: PubMed
  151. Meyerhardt JA, Stuart K, Fuchs CS, Zhu AX, Earle CC, Bhargava P, Blaszkowsky L, Enzinger P, Mayer RJ, Battu S, Lawrence C, Ryan DP. Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer. Ann Oncol. 2007 Jul; 18(7):1185-9. PMID: 17483115.
    View in: PubMed
  152. Ogino S, Meyerhardt JA, Kawasaki T, Clark JW, Ryan DP, Kulke MH, Enzinger PC, Wolpin BM, Loda M, Fuchs CS. CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. Virchows Arch. 2007 May; 450(5):529-37. PMID: 17372756.
    View in: PubMed
  153. Berkenblit A, Eder JP, Ryan DP, Seiden MV, Tatsuta N, Sherman ML, Dahl TA, Dezube BJ, Supko JG. Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 1):584-90. PMID: 17255281.
    View in: PubMed
  154. Meyerhardt JA, Clark JW, Supko JG, Eder JP, Ogino S, Stewart CF, D'Amato F, Dancey J, Enzinger PC, Zhu AX, Ryan DP, Earle CC, Mayer RJ, Michelini A, Kinsella K, Fuchs CS. Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. Cancer Chemother Pharmacol. 2007 Oct; 60(5):661-70. PMID: 17216531.
    View in: PubMed
  155. Ryan DP. Adjuvant Therapy for Pancreatic Cancer. UpToDate. 2007; www.uptodate.com.
  156. Ryan DP and Willett CG. Clinical Features, Staging, and Treatment of Anal Cancer. UpToDate. 2007; www.uptodate.com.
  157. Ryan DP. Chemotherapy for Advanced Pancreatic Cancer. UpToDate. 2007; www.uptodate.com.
  158. Ryan DP and Mamon H. Management of Locally Advanced Pancreatic Cancer. UpToDate. 2007; www.uptodate.com.
  159. Ryan DP and Willett CG. Classification and Epidemiology of Anal Cancer. UpToDate. 2007; www.uptodate.com.
  160. Ryan DP, O'Neil BH, Supko JG, Rocha Lima CM, Dees EC, Appleman LJ, Clark J, Fidias P, Orlowski RZ, Kashala O, Eder JP, Cusack JC. A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors. Cancer. 2006 Dec 01; 107(11):2688-97. PMID: 17075878.
    View in: PubMed
  161. Ryan DP, Appleman LJ, Lynch T, Supko JG, Fidias P, Clark JW, Fishman M, Zhu AX, Enzinger PC, Kashala O, Cusack J, Eder JP. Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors. Cancer. 2006 Nov 15; 107(10):2482-9. PMID: 17036355.
    View in: PubMed
  162. Ryan DP. Nonsurgical approaches to colorectal cancer. Oncologist. 2006 Oct; 11(9):999-1002. PMID: 17030641.
    View in: PubMed
  163. Wolpin BM, Clark JW, Meyerhardt JA, Earle CC, Ryan DP, Enzinger PC, Zhu AX, Blaszkowsky L, Battu S, Fuchs CS. Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2006 Sep; 6(3):208-13. PMID: 17026790.
    View in: PubMed
  164. Kulke MH, Bergsland EK, Ryan DP, Enzinger PC, Lynch TJ, Zhu AX, Meyerhardt JA, Heymach JV, Fogler WE, Sidor C, Michelini A, Kinsella K, Venook AP, Fuchs CS. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol. 2006 Aug 01; 24(22):3555-61. PMID: 16877721.
    View in: PubMed
  165. Kwak EL, Jankowski J, Thayer SP, Lauwers GY, Brannigan BW, Harris PL, Okimoto RA, Haserlat SM, Driscoll DR, Ferry D, Muir B, Settleman J, Fuchs CS, Kulke MH, Ryan DP, Clark JW, Sgroi DC, Haber DA, Bell DW. Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 1):4283-7. PMID: 16857803; PMCID: PMC3807136.
  166. Garland LL, Hidalgo M, Mendelson DS, Ryan DP, Arun BK, Lovalvo JL, Eiseman IA, Olson SC, Lenehan PF, Eder JP. A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 1):4274-82. PMID: 16857802.
    View in: PubMed
  167. Zhu AX, Clark JW, Ryan DP, Meyerhardt JA, Enzinger PC, Earle CC, Fuchs CS, Regan E, Anbe H, Houghton M, Zhang J, Urrea P, Kulke MH. Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer. Cancer Chemother Pharmacol. 2007 Feb; 59(3):285-93. PMID: 16786333.
    View in: PubMed
  168. Kulke MH, Wu B, Ryan DP, Enzinger PC, Zhu AX, Clark JW, Earle CC, Michelini A, Fuchs CS. A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors. Dig Dis Sci. 2006 Jun; 51(6):1033-8. PMID: 16865563.
    View in: PubMed
  169. Meyerhardt JA, Heseltine D, Ogino S, Clark JW, Enzinger PC, Ryan DP, Earle CC, Zhu AX, Fuchs CS. Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer. Clin Colorectal Cancer. 2006 May; 6(1):59-65. PMID: 16796793.
    View in: PubMed
  170. Ryan DP, Niedzwiecki D, Hollis D, Mediema BE, Wadler S, Tepper JE, Goldberg RM, Mayer RJ. Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901. J Clin Oncol. 2006 Jun 01; 24(16):2557-62. PMID: 16636336.
    View in: PubMed
  171. Zhu AX, Blaszkowsky LS, Ryan DP, Clark JW, Muzikansky A, Horgan K, Sheehan S, Hale KE, Enzinger PC, Bhargava P, Stuart K. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006 Apr 20; 24(12):1898-903. PMID: 16622265.
    View in: PubMed
  172. Meyerhardt JA, Zhu AX, Enzinger PC, Ryan DP, Clark JW, Kulke MH, Earle CC, Vincitore M, Michelini A, Sheehan S, Fuchs CS. Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. J Clin Oncol. 2006 Apr 20; 24(12):1892-7. PMID: 16622264.
    View in: PubMed
  173. George S, Desai J, Paul Eder J, Manola J, Ryan DP, Appleman LJ, Demetri GD. Selective kinase inhibition with daily imatinib intensifies toxicity of chemotherapy in patients with solid tumours. Eur J Cancer. 2006 May; 42(7):864-70. PMID: 16503137.
    View in: PubMed
  174. McCollum AD, Wu B, Clark JW, Kulke MH, Enzinger PC, Ryan DP, Earle CC, Michelini A, Fuchs CS. The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer. Am J Clin Oncol. 2006 Feb; 29(1):40-4. PMID: 16462501.
    View in: PubMed
  175. Bendell JC, Lauwers GY, Willett C, Clark JW, Warshaw AL, Wain JC, Ryan DP. Pancreatoblastoma in a teenage patient. Clin Adv Hematol Oncol. 2006 Feb; 4(2):150-3; discussion 154. PMID: 16728924.
    View in: PubMed
  176. Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Vincitore M, Michelini A, Fuchs CS. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol. 2006 Jan 20; 24(3):401-6. PMID: 16421420.
    View in: PubMed
  177. Ryan DP and Willett CG. Classification and Epidemiology of Anal Cancer. UpToDate. 2006; www.uptodate.com.
  178. Ryan DP. Novel Thearpies in Colon Cancer. Current Colorectal Cancer Reports. 2006; 2(3):116-119.
  179. Ryan DP. Chemotherapy for Advanced Pancreatic Cancer. UpToDate. 2006; www.uptodate.com.
  180. Ryan DP, Garcia-Carbonero R, and Chabner BA. Cytidine Analogues. Ed Chabner BA and Longo DL. Cancer Chemotherapy and Biotherapy. 2006.
  181. Chabner BA, Amrein PC, Druker B, Michaelson MD, Mitsiades CS, Goss PA, Ryan DP, Ramachandra S, Richardson PG, Supko JG, Wilson WH. Antineoplastic Agents. Goodman and Gilman's Pharmacologic Basis of Therapuetics. 2006.
  182. Ryan DP. Management of Locally Advanced Pancreatic Cancer. UpToDate. 2006; www.uptodate.com.
  183. Ryan DP. Adjuvant Therapy for Pancreatic Cancer. UpToDate. 2006; www.uptodate.com.
  184. Ryan DP and Willett CG. Clinical Features, Staging, and Treatment of Anal Cancer. UpToDate. 2006; www.uptodate.com.
  185. Eder JP, Ryan DP, Appleman L, Zhu AX, Puchalski T, He X, Sonnichsen DS, Cooper M, Wright J, Clark JW, Supko JG. Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2006 Jul; 58(1):107-16. PMID: 16362299.
    View in: PubMed
  186. Enzinger PC, Kulke MH, Clark JW, Ryan DP, Kim H, Earle CC, Vincitore MM, Michelini AL, Mayer RJ, Fuchs CS. A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma. Dig Dis Sci. 2005 Dec; 50(12):2218-23. PMID: 16416165.
    View in: PubMed
  187. Cunningham C, Appleman LJ, Kirvan-Visovatti M, Ryan DP, Regan E, Vukelja S, Bonate PL, Ruvuna F, Fram RJ, Jekunen A, Weitman S, Hammond LA, Eder JP. Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors. Clin Cancer Res. 2005 Nov 01; 11(21):7825-33. PMID: 16278405.
    View in: PubMed
  188. Willett CG, Boucher Y, Duda DG, di Tomaso E, Munn LL, Tong RT, Kozin SV, Petit L, Jain RK, Chung DC, Sahani DV, Kalva SP, Cohen KS, Scadden DT, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Shellito PC, Mino-Kenudson M, Lauwers GY. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol. 2005 Nov 01; 23(31):8136-9. PMID: 16258121.
    View in: PubMed
  189. Ogino S, Meyerhardt JA, Cantor M, Brahmandam M, Clark JW, Namgyal C, Kawasaki T, Kinsella K, Michelini AL, Enzinger PC, Kulke MH, Ryan DP, Loda M, Fuchs CS. Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin Cancer Res. 2005 Sep 15; 11(18):6650-6. PMID: 16166444.
    View in: PubMed
  190. Hamilton AL, Eder JP, Pavlick AC, Clark JW, Liebes L, Garcia-Carbonero R, Chachoua A, Ryan DP, Soma V, Farrell K, Kinchla N, Boyden J, Yee H, Zeleniuch-Jacquotte A, Wright J, Elliott P, Adams J, Muggia FM. Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle. J Clin Oncol. 2005 Sep 01; 23(25):6107-16. PMID: 16135477.
    View in: PubMed
  191. Garcia-Carbonero R, Supko JG, Maki RG, Manola J, Ryan DP, Harmon D, Puchalski TA, Goss G, Seiden MV, Waxman A, Quigley MT, Lopez T, Sancho MA, Jimeno J, Guzman C, Demetri GD. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol. 2005 Aug 20; 23(24):5484-92. PMID: 16110008.
    View in: PubMed
  192. Clark JW, Eder JP, Ryan D, Lathia C, Lenz HJ. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res. 2005 Aug 01; 11(15):5472-80. PMID: 16061863.
    View in: PubMed
  193. Willett CG, Czito BG, Bendell JC, Ryan DP. Locally advanced pancreatic cancer. J Clin Oncol. 2005 Jul 10; 23(20):4538-44. PMID: 16002845.
    View in: PubMed
  194. Ryan DP, Fernandez-del Castillo C, Willett CG, Brugge WR, Sahani D, Brachtel EF. Case records of the Massachusetts General Hospital. Case 20-2005. A 58-year-old man with locally advanced pancreatic cancer. N Engl J Med. 2005 Jun 30; 352(26):2734-41. PMID: 15987923.
    View in: PubMed
  195. Gribben JG, Ryan DP, Boyajian R, Urban RG, Hedley ML, Beach K, Nealon P, Matulonis U, Campos S, Gilligan TD, Richardson PG, Marshall B, Neuberg D, Nadler LM. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res. 2005 Jun 15; 11(12):4430-6. PMID: 15958627.
    View in: PubMed
  196. Zhu AX, Fuchs CS, Clark JW, Muzikansky A, Taylor K, Sheehan S, Tam K, Yung E, Kulke MH, Ryan DP. A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma. Oncologist. 2005 Jun-Jul; 10(6):392-8. PMID: 15967833.
    View in: PubMed
  197. Kalva SP, Sahani DV, Ryan D, Fischman AJ, Hahn PF, Mueller P, Saini S. Detection of liver metastases from gastrointestinal cancer: comparision of high resolution MnDPDP enhanced MRI and FDG-PET. Acad Radiol. 2005 May; 12 Suppl 1:S17-20. PMID: 16106540.
    View in: PubMed
  198. Bendell JC, Eder JP, Clark JW, Fidias P, Lynch TJ, Seiden MV, Ryan DP. Phase I dose-escalation study of tezacitabine in combination with 5-fluorouracil in patients with advanced solid tumors. Cancer. 2005 May 01; 103(9):1925-31. PMID: 15772958.
    View in: PubMed
  199. Tseng JF, Willett CG, Fernandez-del Castillo C, Ryan DP, Clark JW, Zhu AX, Rattner DW, Winkelmann JL, Warshaw AL. Patients undergoing treatment for pancreatic adenocarcinoma can mount an effective immune response to vaccinations. Pancreatology. 2005; 5(1):67-74. PMID: 15775701.
    View in: PubMed
  200. Willett CG, Del Castillo CF, Shih HA, Goldberg S, Biggs P, Clark JW, Lauwers G, Ryan DP, Zhu AX, Warshaw AL. Long-term results of intraoperative electron beam irradiation (IOERT) for patients with unresectable pancreatic cancer. Ann Surg. 2005 Feb; 241(2):295-9. PMID: 15650640; PMCID: PMC1356915.
  201. Ryan DP. Chemotherapy for Advanced Pancreatic Cancer. UpToDate. 2005; www.uptodate.com.
  202. Ryan DP. The integration of bioilogic agents into the current systemic management of rectal cancer. Current Colorectal Cancer Reports. 2005; 1:58-62.
  203. Ryan DP. Adjuvant Therapy for Pancreatic Cancer. UpToDate. 2005; www.uptodate.com.
  204. Ryan DP and Willett CG. Classification and Epidemiology of Anal Cancer. UpToDate. 2005; www.uptodate.com.
  205. Ryan DP. Management of Locally Advanced Pancreatic Cancer. UpToDate. 2005; www.uptodate.com.
  206. Ryan DP and Willett CG. Clinical Features, Staging, and Treatment of Anal Cancer. UpToDate. 2005; www.uptodate.com.
  207. Demetri GD, Titton RL, Ryan DP, Fletcher CD. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 32-2004. A 68-year-old man with a large retroperitoneal mass. N Engl J Med. 2004 Oct 21; 351(17):1779-87. PMID: 15496628.
    View in: PubMed
  208. McCollum AD, Kulke MH, Ryan DP, Clark JW, Shulman LN, Mayer RJ, Bartel S, Fuchs CS. Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. Am J Clin Oncol. 2004 Oct; 27(5):485-8. PMID: 15596916.
    View in: PubMed
  209. Heymach JV, Desai J, Manola J, Davis DW, McConkey DJ, Harmon D, Ryan DP, Goss G, Quigley T, Van den Abbeele AD, Silverman SG, Connors S, Folkman J, Fletcher CD, Demetri GD. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Clin Cancer Res. 2004 Sep 01; 10(17):5732-40. PMID: 15355900.
    View in: PubMed
  210. Garcia-Carbonero R, Supko JG, Manola J, Seiden MV, Harmon D, Ryan DP, Quigley MT, Merriam P, Canniff J, Goss G, Matulonis U, Maki RG, Lopez T, Puchalski TA, Sancho MA, Gomez J, Guzman C, Jimeno J, Demetri GD. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol. 2004 Apr 15; 22(8):1480-90. PMID: 15084621.
    View in: PubMed
  211. Ryan DP, Eder JP, Puchlaski T, Seiden MV, Lynch TJ, Fuchs CS, Amrein PC, Sonnichsen D, Supko JG, Clark JW. Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 given as a 1-hour intravenous infusion in patients with advanced solid tumors. Clin Cancer Res. 2004 Apr 01; 10(7):2222-30. PMID: 15073096.
    View in: PubMed
  212. Eder JP, Garcia-Carbonero R, Clark JW, Supko JG, Puchalski TA, Ryan DP, Deluca P, Wozniak A, Campbell A, Rothermel J, LoRusso P. A phase I trial of daily oral 4'- N -benzoyl-staurosporine in combination with protracted continuous infusion 5-fluorouracil in patients with advanced solid malignancies. Invest New Drugs. 2004 Apr; 22(2):139-50. PMID: 14739662.
    View in: PubMed
  213. Zhu AX, Puchalski TA, Stanton VP, Ryan DP, Clark JW, Nesbitt S, Charlat O, Kelly P, Kreconus E, Chabner BA, Supko JG. Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancer. Clin Colorectal Cancer. 2004 Feb; 3(4):225-34. PMID: 15025795.
    View in: PubMed
  214. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004 Feb; 10(2):145-7. PMID: 14745444; PMCID: PMC2693485.
  215. Ryan DP and Willett CG. Classification and Epidemiology of Anal Cancer. UpToDate. 2004; www.uptodate.com.
  216. Ryan DP. Adjuvant Therapy for Pancreatic Cancer. UpToDate. 2004; www.uptodate.com.
  217. Ryan DP. Management of Locally Advanced Pancreatic Cancer. UpToDate. 2004; www.uptodate.com.
  218. Ryan DP and Willett CG. Clinical Features, Staging, and Treatment of Anal Cancer. UpToDate. 2004; www.uptodate.com.
  219. Ryan DP. Chemotherapy for Advanced Pancreatic Cancer. UpToDate. 2004.
  220. Kulke MH, Kim H, Stuart K, Clark JW, Ryan DP, Vincitore M, Mayer RJ, Fuchs CS. A phase II study of docetaxel in patients with metastatic carcinoid tumors. Cancer Invest. 2004; 22(3):353-9. PMID: 15493355.
    View in: PubMed
  221. Wright FC, Ryan DP, Dodge JE, Last LD, Law CH, Smith AJ. Identifying educationally influential specialists: issues arising from the use of "classic" criteria. J Contin Educ Health Prof. 2004; 24(4):213-26. PMID: 15709561.
    View in: PubMed
  222. Supko JG, Eder JP, Ryan DP, Seiden MV, Lynch TJ, Amrein PC, Kufe DW, Clark JW. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors. Clin Cancer Res. 2003 Nov 01; 9(14):5178-86. PMID: 14613997.
    View in: PubMed
  223. Bendell JC, Ryan DP. Current perspectives on anal cancer. Oncology (Williston Park). 2003 Apr; 17(4):492-7, 502-3; discussion 503, 507-9. PMID: 12735144.
    View in: PubMed
  224. Bendell JC, Ryan DP, and Willett CG. Recent advances in the combined-modality treatment of pancreatic cancer. Medscape (http://www.medscape.com/viewprogram/2210). 2003.
  225. Michaelson MD, Ryan DP, Fuchs CS, Supko JG, Garcia-Carbonero R, Paul Eder J, Clark JW. A Phase I study of 9-nitrocamptothecin given concurrently with capecitabine in patients with refractory, metastatic solid tumors. Cancer. 2003 Jan 01; 97(1):148-54. PMID: 12491516.
    View in: PubMed
  226. Ryan DP, Clark JW, Kulke MH, Fuchs CS, Earle CC, Enzinger PC, Stuart K, Catarius KJ, Winkelmann J, Mayer RJ. A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer. Cancer Invest. 2003; 21(4):505-11. PMID: 14533439.
    View in: PubMed
  227. Ryan DP. Pancreatic Cancer Therapy. Medscape. 2003; Available at http://www.medsca.
  228. Ryan DP. Adjuvant Therapy for Pancreatic Cancer. UpToDate. 2003; www.uptodate.com.
  229. Ryan DP. Management of Locally Advanced Pancreatic Cancer. UpToDate. 2003; www.uptodate.com.
  230. Ryan DP. Chemotherapy for Advanced Pancreatic Cancer. UpToDate. 2003.
  231. Ryan DP and Willett CG. Clinical Features, Staging, and Treatment of Anal Cancer. UpToDate. 2003; www.uptodate.com.
  232. Ryan DP. Anal Carcinoma. Eds Furie B, Cassileth PA, Atkins MB, and Mayer RJ. Clinical Hematology Presentation, Diagnosis, and treatment. 2003.
  233. Ryan DP and Willett CG. Classification and Epidemiology of Anal Cancer. UpToDate. 2003; www.uptodate.com.
  234. Eder JP, Supko JG, Clark JW, Puchalski TA, Garcia-Carbonero R, Ryan DP, Shulman LN, Proper J, Kirvan M, Rattner B, Connors S, Keogan MT, Janicek MJ, Fogler WE, Schnipper L, Kinchla N, Sidor C, Phillips E, Folkman J, Kufe DW. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol. 2002 Sep 15; 20(18):3772-84. PMID: 12228197.
    View in: PubMed
  235. Kulke MH, Demetri GD, Sharpless NE, Ryan DP, Shivdasani R, Clark JS, Spiegelman BM, Kim H, Mayer RJ, Fuchs CS. A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. Cancer J. 2002 Sep-Oct; 8(5):395-9. PMID: 12416897.
    View in: PubMed
  236. Puchalski TA, Ryan DP, Garcia-Carbonero R, Demetri GD, Butkiewicz L, Harmon D, Seiden MV, Maki RG, Lopez-Lazaro L, Jimeno J, Guzman C, Supko JG. Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity. Cancer Chemother Pharmacol. 2002 Oct; 50(4):309-19. PMID: 12357306.
    View in: PubMed
  237. Fuchs CS, Clark JW, Ryan DP, Kulke MH, Kim H, Earle CC, Vincitore M, Mayer RJ, Stuart KE. A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer. 2002 Jun 15; 94(12):3186-91. PMID: 12115351.
    View in: PubMed
  238. Seiden MV, Ng SW, Supko JG, Ryan DP, Clark JW, Lynch T, Huang KC, Kwiatkowski D, Skarin A, Eder JP. A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors. Clin Cancer Res. 2002 Mar; 8(3):691-7. PMID: 11895897.
    View in: PubMed
  239. Ryan DP, Willett CG. Management of locally advanced adenocarcinoma of the pancreas. Hematol Oncol Clin North Am. 2002 Feb; 16(1):95-103. PMID: 12063831.
    View in: PubMed
  240. Ryan DP, Kulke MH, Fuchs CS, Grossbard ML, Grossman SR, Morgan JA, Earle CC, Shivdasani R, Kim H, Mayer RJ, Clark JW. A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma. Cancer. 2002 Jan 01; 94(1):97-103. PMID: 11815964.
    View in: PubMed
  241. Ryan DP and Willett CG. Clinical Features, Staging, and Treatment of Anal Cancer. UpToDate. 2002; www.uptodate.com.
  242. Ryan DP. Adjuvant Therapy for Pancreatic Cancer. UpToDate. 2002; www.uptodate.com.
  243. Ryan DP, Puchalski T, Supko JG, Harmon D, Maki R, Garcia-Carbonero R, Kuhlman C, Winkelman J, Merriam P, Quigley T, Jimeno J, Manola J, Demetri GD. A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors. Oncologist. 2002; 7(6):531-8. PMID: 12490740.
    View in: PubMed
  244. Ryan DP. Chemotherapy for Advanced Pancreatic Cancer. UpToDate. 2002.
  245. Ryan DP. Management of Locally Advanced Pancreatic Cancer. UpToDate. 2002; www.uptodate.com.
  246. Ryan DP and Willett CG. Classification and Epidemiology of Anal Cancer. UpToDate. 2002; www.uptodate.com.
  247. Earle CC, Chen WY, Ryan DP, Mayer RJ. Oxaliplatin-induced Evan's syndrome. Br J Cancer. 2001 Feb 02; 84(3):441. PMID: 11161414; PMCID: PMC2363741.
  248. Ryan DP, Supko JG, Eder JP, Seiden MV, Demetri G, Lynch TJ, Fischman AJ, Davis J, Jimeno J, Clark JW. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin Cancer Res. 2001 Feb; 7(2):231-42. PMID: 11234874.
    View in: PubMed
  249. Enker WE, Martz J, Tepper JE, Ryan DP, and Mayer RJ. Rectak Cancer: Management of Locoregional Disease. Gastrointestinal Oncology - Principles and Practice. 2001.
  250. Ryan DP and Willett CG. Classification and Epidemiology of Anal Cancer. UpToDate. 2001; www.uptodate.com.
  251. Ryan DP. Chemotherapy for Advanced Pancreatic Cancer. UpToDate. 2001; www.uptodate.com.
  252. Garcia-Carbonero R, Ryan DP, and Chabner B. . Cytidine Analogues. Eds Chabner BA and Longo DL. Cancer Chemotherapy and Biotherapy. 2001.
  253. Ryan DP and Willett CG. Clinical Features, Staging, and Treatment of Anal Cancer. UpToDate. 2001; www.uptodate.com.
  254. Ryan DP and Willett CG. Anal Cancer. Editor Willett CG. Atlas of Clinical Oncology: Cancers of the Lower Gastrointestinal Tract. 2001.
  255. Ryan DP. Management of Locally Advanced Pancreatic Cancer. UpToDate. 2001; www.uptodate.com.
  256. Chabner BA, Ryan DP, Paz-Ares L, Garcia-Carbonero R, Calabresi P. Antineoplastic Agents. Goodman and Gilman's Pharmacologic Basis of Therapeutics. 2001.
  257. Ryan DP. Rectal cancer: integrating oxaliplatin into chemoradiation studies. Oncology (Williston Park). 2000 Dec; 14(12 Suppl 11):38-41. PMID: 11204662.
    View in: PubMed
  258. Ryan DP, Mayer RJ. Anal carcinoma: histology, staging, epidemiology, treatment. Curr Opin Oncol. 2000 Jul; 12(4):345-52. PMID: 10888420.
    View in: PubMed
  259. Ryan DP, Compton CC, Mayer RJ. Carcinoma of the anal canal. N Engl J Med. 2000 Mar 16; 342(11):792-800. PMID: 10717015.
    View in: PubMed
  260. Ryan DP, Lynch TJ, Grossbard ML, Seiden MV, Fuchs CS, Grenon N, Baccala P, Berg D, Finkelstein D, Mayer RJ, Clark JW. A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors. Cancer. 2000 Jan 01; 88(1):180-5. PMID: 10618622.
    View in: PubMed
  261. Ryan DP, Penson RT, Ahmed S, Chabner BA, Lynch TJ. Reality testing in cancer treatment: the phase I trial of endostatin. Oncologist. 1999; 4(6):501-8. PMID: 10631694.
    View in: PubMed
  262. Grem JL, Takimoto CH, Multani P, Chu E, Ryan D, Chabner BA, Allegra CJ, Johnston PG. Antimetabolites. Cancer Chemother Biol Response Modif. 1999; 18:1-38. PMID: 10800475.
    View in: PubMed
  263. Ryan DP. Making Sense of Antisense. ASCO online: JCO Highlights. http://www.asco.org/prof/oc/html/f_jcohighlights.htm. 1999.
  264. Ryan DP and Fuchs CS. Chemotherapy of Pancreatic Cancer. Advances in Oncology. 1998; 14(4):11-19.
  265. Ryan DP, Grossbard ML. Pancreatic Cancer: Local Success and Distant Failure. Oncologist. 1998; 3(3):178-188. PMID: 10388102.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Ryan's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (536)
Explore
_
Co-Authors (201)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Tool Page Footer - Harvard Catalyst Tool Page Footer – Harvard Catalyst
Funded by the NIH/NCATS Clinical and Translational Science Award (CTSA) program, grant number UL1TR001102, and through institutional support from Harvard University, Harvard Medical School, Harvard T.H. Chan School of Public Health, Beth Israel Deaconess Medical Center, Boston Children's Hospital, Brigham and Women's Hospital, Massachusetts General Hospital and the Dana Farber Cancer Institute.